{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000050","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.853990+00:00","generated_at":"2026-06-17T10:28:35.331001+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Caribou Biosciences doses first patient in Phase 1 trial of CB-011 for multiple myeloma","bullets":["First patient dosed with CB-011 at dose level 1 (50x10^6 CAR-T cells) in CaMMouflage Phase 1 trial for relapsed/refractory multiple myeloma.","CB-011 is an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking via B2M removal and B2M-HLA-E transgene insertion.","Trial is open-label, 3+3 dose escalation (Part A) followed by dose expansion (Part B); excludes prior CAR-T or BCMA therapy within 3 months.","CB-011 is Caribou's second allogeneic CAR-T program to enter the clinic.","Company plans to continue enrollment at dose level 1 and provide dose clearance updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000050","json":"https://secwatch.observer/filing/0001619856-23-000050.json","markdown":"https://secwatch.observer/filing/0001619856-23-000050.md","text":"https://secwatch.observer/filing/0001619856-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000050/0001619856-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000050/crbu-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:28:35.331001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}